NNC0519-0130 dose-finding trial initiated for weekly subcutaneous injection in individuals with excess body weight

Globally, excess body weight and obesity represent a significant public health challenge, contributing to numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. Current pharmacological interventions often have varying efficacy, side effect profiles, or require frequent dosing, leaving a substantial unmet need for more effective and convenient treatment options. Investigating novel compounds like NNC0519-0130, particularly with a once-weekly dosing regimen, is crucial for improving patient adherence and overall treatment outcomes in weight management.

This 42-week, dose-finding clinical study will investigate the efficacy and safety of a novel medicine, NNC0519-0130, in individuals with excess body weight. Participants will receive NNC0519-0130 at up to 6 different dose levels via 1-2 subcutaneous (SC) injections once weekly. The injections will be administered in the stomach, thigh, or upper arm. The study employs a dose-escalating manner for the experimental arm, with a parallel placebo-controlled arm receiving NNC0519-0130 matched placebo once weekly SC. The primary endpoint is expected to be the change in body weight from baseline.